A new study finds that only 6% of companies plan to dismantle their employee health care plans in the next three to five years. Many employers, however, are looking to implement plan design changes that could affect patients and survivors.

The Ticket To Work program is one of a number of Work Incentives available to those receiving SSI or SSDI.

On last week's Ask The Experts teleconference, a number of questions came in regarding the different government programs employees with cancer often take advantage of. Check out some of these questions on today's blog!

Today was a historic day for the country and those coping with cancer: the Supreme Court of the United States released a decision to uphold the Patient Protection and Affordable Care Act of 2010 (aka 'healthcare reform' or 'Obamacare').

Legal issues is one of the largest needs our users have and we often bring in experts to address them and provide assistance. So when we heard about the National Cancer Legal Services Network (NCLSN), it was only fitting that we spread the word!

Are you receiving SSI or SSDI payments? Do you want to obtain vocational rehabilitation, training, job referrals and other employment support services free of charge? Then the Ticket to Work program is... well... your ticket!

There are a number of organizations that offer free legal assistance to cancer survivors.

HMO…PPO…COPAY…COBRA...oh my! If you’re like me, the world of insurance lingo and policy conditions can feel like you’re standing in the middle of Macy’s on Christmas Eve—confusing, sweat inducing and wishing you could find a lifeboat out of there. But no worries, take a deep breath, we can get through this together.

You may be able to save a bundle on the typically hefty premium charged for COBRA health coverage, thanks to a provision in the stimulus package (formally known as The American Recovery and Reinvestment Act of 2009).

The New York Times ran a terrific story on April 15 about the dilemma facing cancer patients as more and more oral cancer therapies come on the market, replacing conventional intravenous cancer treatments. While the good news is that progress is being made in the development of more effective, better-targeted cancer drugs in pill and capsule form,